The article you requested is
Risperidone and Cytochrome P450 3A
J Clin Psychiatry 1997;58:450 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
- Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: We read with great interest the recent article by
Ereshefsky on pharmacokinetics and drug interactions of the
new antipsychotics. This work is timely and provides invaluable
information for clinicians regarding drug interactions with
atypical antipsychotics. In his discussion of cytochrome
P450 3A (CYP3A) isoenzyme induction by carbamazepine,
Ereshefsky relates that metabolism of certain typical and atypical
antipsychotics usually increases when carbamazepine is